{
    "Clinical Trial ID": "NCT00232479",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Group 1",
        "  patients received dose dense herceptin, carboplatin and taxotere"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  HER-2 overexpressing breast cancer",
        "  Clinical stage 2-3B",
        "  Normal ejection fraction",
        "Exclusion Criteria:",
        "  Metastatic disease",
        "  Low ejection fraction"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Patients With Pathologic Complete Response (pCR)",
        "  pCR is defined as the absence of invasive tumor from the surgical specimen of breast and axilla which is obtained after the chemotherapy regimen has been delivered.",
        "  Time frame: determined at the time of surgery which is approximately 16 weeks from the beginning of treatment",
        "Results 1: ",
        "  Arm/Group Title: Group 1",
        "  Arm/Group Description: patients received dose dense herceptin, carboplatin and taxotere",
        "  Overall Number of Participants Analyzed: 44",
        "  Measure Type: Number",
        "  Unit of Measure: participants  19"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 1/46 (2.17%)",
        "  hospitalization [1]1/46 (2.17%)"
    ]
}